Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis

References

• McClungMHarrisSTMillerPDBisphosphonate therapy for osteoporosis: benefits, risks, and drug holidayAm J Med20131261132023177553
   PubMed Web of Science ®Google Scholar
• BoneHGWagmanRBBrandiML10 Years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extensionLancet Diabetes Endocrinol20175751352328546097
   PubMed Web of Science ®Google Scholar
• NakamuraYSuzukiTYoshidaTYamazakiHKatoHVitamin D and calcium are required during denosumab treatment in osteoporosis with rheumatoid arthritisNutrients201795E42828445420
   PubMed Web of Science ®Google Scholar
• SuzukiTNakamuraYTanakaMComparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis. Mod RheumatolEpub201741114
   Google Scholar
• McClungMRole of RANKL inhibition in osteoporosisArthritis Res Ther20079Suppl 1S3 Review
   PubMed Web of Science ®Google Scholar
• KinoshitaHMiyakoshiNKashiwaguraTKasukawaYSugimuraYShimadaYComparison of the efficacy of denosumab and bisphosphonates for treating secondary osteoporosis in patients with rheumatoid arthritisMod Rheumatol201727458258627659808
   PubMed Web of Science ®Google Scholar
• LeeSGParkYEParkSHIncreased frequency of osteoporosis and BMD below the expected range for age among South Korean women with rheumatoid arthritisInt J Rheum Dis201215328929622709491
   PubMed Web of Science ®Google Scholar
• KimSYSchneeweissSLiuJRisk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritisArthritis Res Ther2010124R15420682035
   PubMed Web of Science ®Google Scholar
• RouxSOrcelPBone loss. Factors that regulate osteoclast differentiation: an updateArthritis Res2000245145611094458
   PubMedGoogle Scholar
• IlaniAAMackworth-YoungCGThe role of citrullinated protein antibodies in predicting erosive disease in rheumatoid arthritis: a systematic literature review and meta-analysisInt J Rheumatol2015201572861025821469
   PubMedGoogle Scholar
• HasegawaTKanekoYIzumiKTakeuchiTEfficacy of denosumab combined with bDMARDs on radiographic progression in rheumatoid arthritisJoint Bone Spine20178437938027369650
   PubMed Web of Science ®Google Scholar
• SoenSNew diagnostic criteria and guidelines on osteoporosis. Diagnostic criteria for primary osteoporosis: year 2012 revisionClin Calcium201424323329 Article in Japanese24576928
   PubMedGoogle Scholar
• van der LindenMPKnevelRHuizingaTWvan der Helm-van MilAHClassification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteriaArthritis Rheum2011631374220967854
   PubMed Web of Science ®Google Scholar
• ShimizuTTakahataMKimura-SudaHAutoimmune arthritis deteriorates bone quantity and quality of periarticular bone in a mouse model of rheumatoid arthritisOsteoporos Int201728270971827704183
   PubMed Web of Science ®Google Scholar
• MochizukiTYanoKIkariKEffects of denosumab treatment on bone mineral density and joint destruction in patients with rheumatoid arthritisJ Bone Miner Metab Epub20177510.1007/s00774-017-0848-1
   Web of Science ®Google Scholar
• NakamuraYSuzukiTKatoHDenosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis: denosumab improves bone mineral density in osteoporosis with rheumatoid arthritisArch Osteoporos20171218028936606
   PubMed Web of Science ®Google Scholar
• HashizumeMTanSLTakanoJTocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insightsInt Rev Immunol201534326527925099958
   PubMed Web of Science ®Google Scholar
• AdamiGOrsoliniGAdamiSEffects of TNF inhibitors on parathyroid hormone and Wnt signaling antagonists in rheumatoid arthritisCalcif Tissue Int201699436036427307275
   PubMed Web of Science ®Google Scholar
• ZerbiniCAFClarkPMendez-SanchezLIOF Chronic Inflammation and Bone Structure (CIBS) Working GroupBiologic therapies and bone loss in rheumatoid arthritisOsteoporos Int201728242944627796445
   PubMed Web of Science ®Google Scholar
• SmolenJSVan Der HeijdeDMClairEWStActive-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study GroupPredictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trialArthritis Rheum20065470271016508926
   PubMed Web of Science ®Google Scholar
• EmeryPBreedveldFCHallSComparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trialLancet2008372963637538218635256
   PubMed Web of Science ®Google Scholar
• BreedveldFCWeismanMHKavanaughAFThe PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatmentArthritis Rheum2006541263716385520
   PubMed Web of Science ®Google Scholar
• YamanakaHIshiguroNTakeuchiTRecovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trialRheumatology (Oxford)20145390491324441150
   PubMed Web of Science ®Google Scholar
• TanakaYHarigaiMTakeuchiTGO-FORTH Study GroupGolimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH studyAnn Rheum Dis201271681782422121129
   PubMed Web of Science ®Google Scholar
• AtsumiTYamamotoKTakeuchiTThe first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progressionAnn Rheum Dis2016751758326139005
   PubMed Web of Science ®Google Scholar
• KotakeSSatoKKimKJInterleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formationJ Bone Miner Res199611188958770701
   PubMed Web of Science ®Google Scholar
• SmolenJSBeaulieuARubbert-RothAOPTION InvestigatorsEffect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialLancet2008371961798799718358926
   PubMed Web of Science ®Google Scholar
• BathonJRoblesMXimenesACSustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomesAnn Rheum Dis201170111949195621821865
   PubMed Web of Science ®Google Scholar
• Roser-PageSVikulinaTZayzafoonMWeitzmannMNCTLA-4Ig-induced T cell anergy promotes Wnt-10b production and bone formation in a mouse modelArthritis Rheumatol201466499099924757150
   PubMed Web of Science ®Google Scholar
• OrsoliniGAdamiGAdamiSShort-term effects of TNF inhibitors on bone turnover markers and bone mineral density in rheumatoid arthritisCalcif Tissue Int201698658058526887973
   PubMed Web of Science ®Google Scholar
• KumeKAmanoKYamadaSThe effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritisRheumatology (Oxford)201453590090324441151
   PubMed Web of Science ®Google Scholar